Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens - Hallo friendsTHE LEK NEWS, In the article you read this time with the title Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens
link : Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens

Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens

Journal of viral hepatitis
Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens
Neeru Bhardwaj, Manon Ragonnet-Cronin, Ben Murrell, Krishna Chodavarapu,  Ross Martin, Silvia Chang, Michael D. Miller, Jordan J. Feld, Mark Sulkowski, Alessandra Mangia, Joel O. Wertheim, Anu Osinusi, John McNally, Diana Brainard, Hongmei Mo, Evguenia S. Svarovskaia

Download Full-Text Article
http://ift.tt/2zbEsXB

Shared By Henry E. Chang 

Abstract
Treatment with the direct-acting antiviral agent (DAA) sofosbuvir (SOF), an NS5B inhibitor, and velpatasvir (VEL), an NS5A inhibitor, demonstrates viral cure rates of ≥95% in hepatitis C virus (HCV) genotypes (GT) 1-6. Here we investigated intrapatient HCV diversity in NS5A and NS5B using Shannon entropy to examine the relationship between viral diversity and treatment outcome. At baseline, HCV diversity was lowest in patients infected with HCV GT3 as compared to the other GTs, and viral diversity was greater in NS5A than NS5B (p<0.0001). Treatment outcome with SOF/VEL or the comparator regimen of SOF with ribavirin (RBV) was not correlated with baseline diversity. However, among persons treated with SOF/VEL, a decrease in diversity from baseline was observed at relapse in the majority virologic failures, consistent with a viral bottleneck event at relapse. In contrast, an increase in diversity was observed in 27% of SOF+RBV virologic failures. We investigated whether the increase in diversity was due to an increase in the transition rate, one mode of potential RBV-mediated mutagenesis; however, we found no evidence of this mechanism. Overall, we did not observe that viral diversity at baseline influenced treatment outcome, but the diversity changes observed at relapse can improve our understanding of RBV viral suppression in vivo.

Continue to article...

Follow On Twitter: Henry E. Chang
Download hepatitis C clinical research articles made available through an online storage and file sharing platform provided by Henry E. Chang.

Thus Article Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens

That's an article Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Intrapatient viral diversity & treatment outcomes in patients with genotype 3a HCV infection on SOF-containing regimens with the link address https://theleknews.blogspot.com/2017/11/intrapatient-viral-diversity-treatment.html

Tweet

Subscribe to receive free email updates: